L-5-Hydroxytryptophan Can Prevent Nociceptive Disorders in Man

  • Maria Nicolodi
  • Federigo Sicuteri
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 467)


Prevention of primary pain is a new topic, endowed with social and economic interest. We observed that L-5-HTP can induce a significant decrease of the cropping out of migraine, the commonest primary pain. This finding seems interesting, since it represents the first data in the field and was obtained in a prospective, long-term, placebo controlled study. The result obtained suggests that CNS abnormalities underlying the mechanism of migraine can be changed by L-5-HTP, if the amino acid is administered to subjects who are predisposed to headache.

Address for correspondence: Federigo Sicuteri, Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache & Department of Internal Medicine, 18 Viale Pieraccini, 50139 Florence, Italy, Tel: +39 (55) 59.91.86, Fax: +39 (55) 59.75.00, e-mail:


Pain Threshold Migraine Attack Migraine Pain Migraine Sufferer Unbearable Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bono, G., Micieli, G., Sances, G., Calvani, M., and Nappi, G., 1984, L 5-HTP treatment in primary headaches: an attempt at clinical identification of responsive patients. Cephalalgia, 4:159–165.PubMedCrossRefGoogle Scholar
  2. Hardy, J.D., Wolff, H.G., and Goodell, H., 1952, Pain sensitivity and reactions. Williams and Wilkins: Baltimore.Google Scholar
  3. Lewis, T., 1942, Pain McMillian: New York.Google Scholar
  4. Llewelyn, M.B., Azami, J., and Roberts, T.S., 1984, The effect of modification of 5-hydroxytryptamine funtion in nucleus raphe magnus on nociceptive threshold. Brain Res 306:165–170.PubMedCrossRefGoogle Scholar
  5. Nicolodi, M. and Sicuteri, F., 1993, Visceral heterotopic allodynia and hyperalgesia unmask the hidden dimension of nociceptive disorder in migraine. In: New trends in referred pain and hyperalgesia (L. Vecchiet, D. Albe-Fessard, and U. Lindblom eds.), 309–312, Amsterdam: Elsevier.Google Scholar
  6. Nicolodi, M. and Sicuteri, F., 1994, Hyperalgesia and over-reaction in migraine as signs of central pain. In. Advances in headache research Vol. 3 (F. Clifford Rose, ed.) pp 45–47, Smith-Gordon: London.Google Scholar
  7. Nicolodi, M. and Sicuteri, F., 1998, The detection of inheritable, pain-independent “third hyperalgesia” in man. In: Management of pain: A world perspective, Vol. 3 (J.A. De Vera, W. Parris, and S. Erdine, eds.), pp 263–266, Monduzzi Internat. Proc Div: Bologna.Google Scholar
  8. Nicolodi, M., Sicuteri, F., Bartolini, A., Ghelardini, C., and Coppola, G., 1994, Central actions of sumatriptan in animals and in man. In: New advances in headache research, Vol. 4 (F. Clifford-Rose, ed.) pp 183–188.Google Scholar
  9. Nicolodi, M., Sicuteri, R., Coppola, G., Greco, E., Pietrini, U., and Sicuteri, F., 1994, Visceral pain threshold is deeply lowered far from the head in migraine. Headache 34:12–19.PubMedCrossRefGoogle Scholar
  10. Nicolodi, M., Sicuteri, F., Ghelardini, C., Galeotti, N., and Bartolini, A., 1997, Proposal of an animal model to test specific acute drugs for migraine attacks. Cephalalgia 17:400.CrossRefGoogle Scholar
  11. Santucci, M., Cortelli, P., Rossi, P.G., Baruzzi, A., and Sacquegna, T., 1986, L 5-hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double blind crossover study. Cephalalgia 6:155–157.PubMedCrossRefGoogle Scholar
  12. Sicuteri, F., 1972, 5-Hydroxytryptophan in the prophylaxis of migraine. Pharmacol Res Commun. 4:213–217.CrossRefGoogle Scholar
  13. Sicuteri, F., 1978, Headache as the most common disease of the antinociceptive system: Analogies with morphine abstinence, In: Advances in pain research and therapy Vol. 3 (J.J. Bonica, J.C. Liebeskind, and D.G. Albe-Fessard, eds.) pp 359–365, Raven Press: New York.Google Scholar
  14. Sicuteri, F., Amselmi, B., and Del Bianco, P.L., 1973, 5-hydroxytryptamine supersensitivity as a new theory of headache and central pain. A clinical pharmacological approach with p-chlorophenylalanine. Psychopharmacology 29:347–356.CrossRefGoogle Scholar
  15. Sicuteri. F., Nicolodi, M., Del Bianco, P.L., and Del Bene, E., 1997, Decentralization monoamine super-sensitivity of migraine and opiate abstinence: common features and different target mechanisms? Int J Clin Pharm Res XVII (2/3):67–73.Google Scholar
  16. Sweet, W.H., 1991, Deafferentation syndromes in humans: a general discussion. In: Advances in pain research and therapy, Vol. 19 (B.S. Nashold and J. Ovlement-Levitt, eds.) pp 259–274, Raven Press: New York.Google Scholar
  17. Wang, R.I.H., Wiesen, R.L., Treul, S., and Stockdale, S., 1976, A brief anxiety rating scale in evaluation of anxiolytics. J Clin Pharmacol 6:99–105.CrossRefGoogle Scholar
  18. Weiss, K.M., Chackraborty, R., Majumder, P.P., and Smouse P.E., 1982, Problems in the assessment of relative risk of individuals. J Chronic Dis 35:539–551.PubMedCrossRefGoogle Scholar
  19. Willis, W.D., 1988, Anatomy and physiology of descending control of nociceptive responses of dorsal horn neurons: comprehensive review. Prog Brain Res 77:1–29.PubMedCrossRefGoogle Scholar
  20. Wurtman, R.J., 1962, Nutrienti che modificano la funzione cerebrale. Le Scienze 166:54–72.Google Scholar
  21. Zung, W.W., 1965, A self-rating depression scale. Arch Gen Psychiatry 2:63–70.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Maria Nicolodi
    • 1
  • Federigo Sicuteri
    • 1
  1. 1.Department of Internal Medicine and TherapeuticsInteruniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic HeadacheFlorenceItaly

Personalised recommendations